Drug Profile
Research programme: stroke therapy - Chemokine
Alternative Names: CTCE-0501Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Chemokine Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in Canada
- 24 Jul 2007 Preclinical development is ongoing
- 08 Mar 2006 Preclinical trials in Stroke in Canada (unspecified route)